Suppr超能文献

相似文献

1
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.
Biochem J. 2007 Sep 1;406(2):203-7. doi: 10.1042/BJ20070664.
2
LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Eur J Med Chem. 2015 Mar 6;92:890-907. doi: 10.1016/j.ejmech.2015.01.022. Epub 2015 Jan 12.
3
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
J Biol Chem. 2007 Jul 20;282(29):20799-803. doi: 10.1074/jbc.C700095200. Epub 2007 May 29.
4
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74. doi: 10.1073/pnas.0409736102. Epub 2005 Jan 27.
6
Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.
Atherosclerosis. 2009 Mar;203(1):161-5. doi: 10.1016/j.atherosclerosis.2008.10.007. Epub 2008 Oct 17.
7
Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain.
Mol Genet Metab. 2010 Sep;101(1):76-80. doi: 10.1016/j.ymgme.2010.05.003. Epub 2010 Jun 9.
8
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Nat Struct Mol Biol. 2007 May;14(5):413-9. doi: 10.1038/nsmb1235. Epub 2007 Apr 15.
10
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.
Protein Sci. 2016 Nov;25(11):2018-2027. doi: 10.1002/pro.3019. Epub 2016 Oct 15.

引用本文的文献

1
Role of shear stress-induced red blood cell released ATP in atherosclerosis.
Am J Physiol Heart Circ Physiol. 2025 Apr 1;328(4):H774-H791. doi: 10.1152/ajpheart.00875.2024. Epub 2025 Feb 21.
2
Phytaspase Does Not Require Proteolytic Activity for Its Stress-Induced Internalization.
Int J Mol Sci. 2024 Jun 19;25(12):6729. doi: 10.3390/ijms25126729.
3
Research progress in the correlation between SREBP/PCSK9 pathway and lipid metabolism disorders induced by antipsychotics.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Oct 28;48(10):1529-1538. doi: 10.11817/j.issn.1672-7347.2023.230029.
5
The evolving landscape of PCSK9 inhibition in cancer.
Eur J Pharmacol. 2023 Jun 15;949:175721. doi: 10.1016/j.ejphar.2023.175721. Epub 2023 Apr 12.
7
Intercepting IRE1 kinase-FMRP signaling prevents atherosclerosis progression.
EMBO Mol Med. 2022 Apr 7;14(4):e15344. doi: 10.15252/emmm.202115344. Epub 2022 Feb 22.
9

本文引用的文献

1
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
J Biol Chem. 2007 Jul 20;282(29):20799-803. doi: 10.1074/jbc.C700095200. Epub 2007 May 29.
2
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
Structure. 2007 May;15(5):545-52. doi: 10.1016/j.str.2007.04.004.
3
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10.
5
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Nat Struct Mol Biol. 2007 May;14(5):413-9. doi: 10.1038/nsmb1235. Epub 2007 Apr 15.
6
The proprotein convertases are potential targets in the treatment of dyslipidemia.
J Mol Med (Berl). 2007 Jul;85(7):685-96. doi: 10.1007/s00109-007-0172-7. Epub 2007 Mar 10.
8
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
Am J Hum Genet. 2006 Sep;79(3):514-23. doi: 10.1086/507488. Epub 2006 Jul 18.
9
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Hum Mol Genet. 2006 May 1;15(9):1551-8. doi: 10.1093/hmg/ddl077. Epub 2006 Mar 28.
10
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
N Engl J Med. 2006 Mar 23;354(12):1264-72. doi: 10.1056/NEJMoa054013.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验